Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cedila Therapeutics

- PMLiVE

Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

Novartis day

Novartis makes case for NASH candidate tropifexor

Race to market intensifies as rivals strive to win first-in-class

- PMLiVE

Sandoz finally wins FDA approval for Neulasta biosimilar

Follows a three year wait since initial rejection in 2016

Novartis building

Novartis’ Cosentyx misses the mark in Humira head-to-head

Narrowly missed statistical significance for superiority

- PMLiVE

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

Therapy candidate was licensed in a $1bn-plus deal last year

- PMLiVE

Novartis grows in Q3 thanks to stellar performance of key drugs

Cosentyx, Entresto and Zolgensma topped drive sales growth

- PMLiVE

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Head-to-head trial with rival Eylea could boost sales

- PMLiVE

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Has potential in cardiovascular and metabolic diseases

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

- PMLiVE

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Hopes to boost haematology franchise with lead drug Doptelet

- PMLiVE

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'

Novartis building

Novartis points finger at AveXis execs in Zolgensma data scandal

Announces remediation plan including whistleblower scheme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links